Heart Diseases

Introduction

We are delighted to welcome you to the 39th World Congress on Heart Diseases, scheduled to be held on October 20-21, 2025, in Frankfurt, Germany. This prestigious global event will bring together leading cardiologists, researchers, healthcare professionals, and industry experts to explore the latest advancements in cardiovascular medicine under the theme: "Transforming Cardiovascular Health Through Innovative Research and Advanced Technology.

As heart diseases continue to be the leading cause of mortality worldwide, this congress provides a dynamic platform to discuss groundbreaking research, emerging technologies, clinical practices, and innovative strategies aimed at improving cardiovascular outcomes. Through keynote sessions, expert panels, interactive workshops, and poster presentations, participants will engage in high-level discussions and networking opportunities that foster collaboration and knowledge sharing across disciplines.

Join us in Frankfurt—a city known for its scientific spirit and rich culture—for two days of inspiring science, meaningful collaboration, and a shared commitment to advancing global heart health. The city is home to world-class research institutions, making it an ideal setting for a cutting-edge scientific congress. Visitors can enjoy the scenic beauty of the River Main, explore the historic Römer square, and experience vibrant German hospitality. With its excellent connectivity, state-of-the-art conference venues, and rich cultural offerings, Frankfurt provides the perfect backdrop for a truly memorable and impactful event.

Who Should Attend

Attending to heart diseases involves observing, managing, and controlling cardiovascular conditions. The following groups play vital roles in the treatment and care of heart diseases:

Individuals:
Everyone holds a personal responsibility to actively manage their heart health by adopting healthy lifestyles, controlling risk factors, and seeking timely medical care.

Healthcare Providers:
Physicians, cardiologists, nurses, and other healthcare professionals are crucial in diagnosing, treating, and managing heart diseases. They perform procedures, prescribe medications, provide guidance, and monitor patient progress.

Family Members and Caregivers:
Family and caregivers provide essential support for patients with heart conditions. They assist with medication adherence, lifestyle modifications, and emotional support to improve patient outcomes.

Target Audience

• Cardiologists and specialists
• Cardiac surgeons
• Interventional cardiologists
• Electrophysiologists
• Vascular and thoracic surgeons
• Cardiovascular researchers
• Cardiac nurses
• Medical students
• Healthcare administrators
• Pharma and device professionals
• Biomedical engineers
• Clinical trial experts
• Public health experts
• Nutritionists and rehab specialists
• Health informatics experts
• Telemedicine professionals
• Policy makers
• Academic educators
• NGOs and health groups
• Patient advocates
• Emergency medicine staff

Why to Attend

• Learn about the latest heart disease research and treatments.
• Discover cutting-edge technology and AI applications in cardiology.
• Network with leading cardiologists, researchers, and healthcare professionals.
• Gain insights into women’s heart health and special populations.
• Explore innovative approaches in prevention, diagnosis, and rehabilitation.
• Access expert-led workshops and interactive sessions.
• Collaborate on global cardiovascular health challenges and solutions.
• Enhance clinical skills and stay updated with guideline advancements.
• Connect with industry leaders and medical device innovators.
• Contribute to shaping the future of cardiovascular care worldwide.

Sessions and Tracks

Track 01. Coronary Artery Disease

Coronary artery disease results from atherosclerosis, a condition where fatty deposits accumulate inside the coronary arteries, leading to reduced blood flow to the heart muscle. This can cause chest pain (angina), shortness of breath, or myocardial infarction (heart attack) if blood flow is severely blocked. Major risk factors include smoking, hypertension, diabetes, high cholesterol, and sedentary lifestyle. Treatments range from lifestyle changes and medications such as statins and antiplatelets to invasive procedures like angioplasty and coronary artery bypass grafting. Advances in AI have improved early detection through imaging, predictive modeling, and personalized treatment approaches, helping reduce morbidity and mortality rates.

Key Points:

• Atherosclerosis causes narrowing/blockage of coronary arteries.

• Leads to ischemia, angina, myocardial infarction.

• Risk factors: smoking, diabetes, hypertension, high cholesterol.

• Treatments: lifestyle changes, statins, angioplasty, Coronary Artery Bypass Grafting.

• AI aids in risk prediction and imaging interpretation.

Track 02. Heart Failure

Heart failure is a clinical syndrome where the heart cannot pump blood adequately, leading to symptoms like fatigue, swelling, and shortness of breath. Causes include coronary artery disease, hypertension, and cardiomyopathies. It is classified as systolic or diastolic dysfunction. Management involves medications such as ACE inhibitors, beta-blockers, diuretics, lifestyle changes, and device therapy (e.g., defibrillators). Side effects of medications include electrolyte imbalance and renal dysfunction. AI applications in heart failure include remote patient monitoring and predictive analytics for hospitalization risk, enhancing personalized care.

Key Points:

• Inability of heart to supply sufficient blood.

• Symptoms: fatigue, edema, breathlessness.

• Causes: Coronary Artery Disease, hypertension, cardiomyopathy.

• Treatments: medications, lifestyle, devices, heart transplant.

• AI for monitoring and predicting exacerbations.

Track 03. Arrhythmias

Arrhythmias are disorders of the heart’s electrical system causing abnormal rhythms such as atrial fibrillation, ventricular tachycardia, and bradyarrhythmias. These can range from benign to life-threatening and increase risks of stroke and sudden cardiac death. Treatments include antiarrhythmic drugs, catheter ablation, and implantable devices like pacemakers and defibrillators. Side effects of drugs can cause proarrhythmia or organ toxicity. AI-powered wearables enable continuous electrocardiogram monitoring for early detection and better management.

Key Points:

• Abnormal heart rhythms from conduction abnormalities.

• Common types: atrial fibrillation, ventricular tachycardia.

• Treatments: drugs, ablation, pacemakers, implantable cardioverter defibrillators.

• Side effects: proarrhythmia, toxicity.

• AI enhances early detection and monitoring.

Track 04. Hypertension

Hypertension is defined as persistently elevated blood pressure, which damages arteries and increases risk of heart disease, stroke, and kidney failure. It is often called the “silent killer” because it may be asymptomatic. Treatment includes lifestyle modification (diet, exercise) and antihypertensive drugs like ACE inhibitors, calcium channel blockers, and diuretics. Side effects vary but may include cough, fatigue, or electrolyte disturbances. Digital health technologies and AI enable better blood pressure monitoring and adherence to treatment.

Key Points:

• Chronic high blood pressure (≥130/80 mmHg).

• Major risk factor for cardiovascular diseases.

• Management: lifestyle changes, medications.

• Side effects: cough (Angiotensin-Converting Enzyme inhibitors), fatigue (beta-blockers).

• AI supports home monitoring and management.

Track 05. Cardiomyopathies

Cardiomyopathies are diseases affecting the heart muscle that can cause heart failure or arrhythmias. Types include dilated, hypertrophic, and restrictive cardiomyopathies. They may be genetic or acquired. Diagnosis often involves imaging and genetic testing. Treatment includes medications, implantable devices, and in some cases, heart transplantation. Side effects depend on therapy used. AI is increasingly used for genetic data analysis and advanced imaging to tailor treatment.

Key Points:

• Structural and functional abnormalities of heart muscle.

• Types: dilated, hypertrophic, restrictive.

• Symptoms: fatigue, arrhythmia, heart failure.

• Treatments: drugs, implantable cardioverter defibrillator, transplant.

• AI aids diagnosis and personalized treatment.

Track 06. Valvular Heart Disease

Valvular heart disease involves malfunction of one or more heart valves causing stenosis (narrowing) or regurgitation (leakage). Common causes are degenerative changes, rheumatic fever, and infections. Symptoms include breathlessness, fatigue, and heart murmurs. Treatment options include valve repair or replacement, either surgically or via catheter-based techniques. Side effects include bleeding and infection. AI improves valve imaging and surgical planning.

Key Points:

• Valve stenosis or insufficiency impairs cardiac function.

• Causes: degeneration, rheumatic disease, infections.

• Treatments: surgical repair/replacement, transcatheter aortic valve replacement.

• Side effects: bleeding, infection.

• AI aids in diagnosis and procedural planning.

Track 07. Peripheral Artery Disease

Peripheral artery disease is caused by atherosclerosis in peripheral arteries, reducing blood flow to limbs. Symptoms include claudication and limb pain. Risk factors overlap with coronary artery disease . Treatment involves lifestyle changes, antiplatelets, and sometimes revascularization surgery. Side effects of treatment include bleeding from antiplatelets. Severe  peripheral artery disease can cause critical limb ischemia requiring amputation. AI enhances diagnostic accuracy through imaging and predictive risk models.

Key Points:

• Atherosclerosis of peripheral arteries.

• Symptoms: claudication, limb ischemia.

• Treatment: lifestyle, antiplatelets, surgery.

• Side effects: bleeding risks.

• AI improves diagnosis and risk stratification.

Track 08. Myocarditis

Myocarditis is inflammation of the heart muscle, often caused by viral infections or autoimmune processes. It can cause chest pain, arrhythmias, and heart failure. Diagnosis involves cardiac MRI and biopsy. Treatment is supportive with immunosuppressants in select cases. Side effects relate to therapies used. Severe myocarditis can lead to chronic cardiomyopathy. AI is being developed to aid early diagnosis and prognosis.

Key Points:

• Inflammation of heart muscle.

• Causes: infections, autoimmune.

• Symptoms: chest pain, arrhythmia, heart failure.

• Diagnosis: Magnetic resonance imaging, biopsy.

• AI aids in detection and outcome prediction.

Track 09. Pulmonary Hypertension

Pulmonary hypertension is elevated pressure in the pulmonary arteries causing right heart strain and failure. Causes include lung diseases, left heart disease, and chronic thromboembolism. Symptoms are breathlessness and fatigue. Treatment targets underlying causes and includes vasodilators and anticoagulants. Side effects can include hypotension and bleeding. AI assists in diagnostic imaging interpretation and hemodynamic data analysis.

Key Points:

• High blood pressure in lung arteries.

• Causes: lung disease, left heart disease, clots.

• Symptoms: dyspnea, fatigue.

• Treatment: vasodilators, anticoagulants.

• AI supports diagnosis and management.

Track 10. Congenital Heart Disease

Congenital heart disease includes structural defects present at birth. Common defects are septal defects, valve abnormalities, and complex cyanotic lesions. Treatment ranges from observation to surgery. Lifelong monitoring is essential. Complications include arrhythmias and heart failure. AI improves fetal diagnosis and surgical planning via advanced imaging techniques.

Key Points:

• Structural heart defects from birth.

• Types: septal defects, valve malformations.

• Treatments: medical, surgical.

• Lifelong follow-up required.

• AI enhances prenatal diagnosis and care planning.

Track 11. Aortic Aneurysm and Dissection

An aortic aneurysm is a dangerous dilation of the aorta that can rupture or dissect, causing life-threatening hemorrhage. Risk factors include hypertension and connective tissue disorders. Diagnosis is by imaging such as computed tomography angiography. Treatment depends on size and risk: surveillance or surgical repair. Side effects of surgery include bleeding and infection. AI aids detection and risk stratification through imaging analysis.

Key Points:

• Abnormal aortic dilation with rupture risk.

• Risk factors: hypertension, genetic disorders.

• Diagnosed by computed tomography, magnetic resonance imaging.

• Treatment: surveillance, surgery.

• AI enhances imaging interpretation.

Track 12. Lipid Disorders and Atherosclerosis

Lipid disorders, especially elevated low density lipoprotein cholesterol, promote atherosclerosis, leading to cardiovascular disease. Treatments include statins, PCSK9 inhibitors, and lifestyle modification. Statins can cause muscle pain and liver enzyme elevation. Uncontrolled lipid disorders increase risks of heart attack and stroke. AI supports personalized treatment decisions and risk assessment.

Key Points:

• High Low-Density Lipoprotein cholesterol leads to plaque formation.

• Treatments: statins, PCSK9 inhibitors.

• Side effects: myopathy, liver issues.

• Leads to heart attack and stroke risks.

• AI improves risk prediction and therapy choice.

Track 13. Cardio-Oncology

Cardio-oncology focuses on managing cardiovascular side effects of cancer treatments such as chemotherapy and radiation. These treatments may cause cardiotoxicity, arrhythmias, and heart failure. Early detection via biomarkers and imaging is critical. Cardioprotective drugs and therapy adjustments help reduce risk. AI supports risk prediction and monitoring for timely intervention.

Key Points:

• Cardiovascular effects of cancer therapy.

• Risks: cardiotoxicity, heart failure.

• Early detection essential.

• Treatments: cardioprotective drugs, therapy modification.

• AI aids risk stratification and monitoring.

Track 14. Inflammatory Heart Disease

Inflammatory conditions such as pericarditis and infective endocarditis affect heart tissues causing pain, dysfunction, and systemic symptoms. Treatment involves antibiotics and anti-inflammatory agents. Complications include heart failure and embolism. Side effects depend on therapy used. AI aids in diagnosis by interpreting complex imaging and clinical data.

Key Points:

• Inflammation of pericardium or endocardium.

• Causes: infections, autoimmune.

• Treatment: antimicrobials, anti-inflammatories.

• Risks: embolism, heart failure.

• AI improves diagnosis and management.

Track 15. Lifestyle and Cardiovascular Risk

Lifestyle factors like diet, physical activity, smoking, and stress significantly impact cardiovascular health. Poor habits increase risks for hypertension, diabetes, and coronary artery disease. Interventions promote healthy eating, exercise, smoking cessation, and stress reduction. AI-powered apps assist in monitoring and behavioral change. Healthy lifestyle reduces adverse cardiovascular events.

Key Points:

• Diet, exercise, smoking affect heart disease risk.

• Healthy habits reduce cardiovascular events.

• Digital tools aid behavior modification.

• AI personalizes lifestyle interventions.

• Improves overall cardiovascular outcomes.

Track 16. Women and Heart Disease

Heart disease presentation and risk differ in women, often leading to underdiagnosis. Microvascular disease and pregnancy-related cardiomyopathies are more common in women. Hormonal and autoimmune factors also play roles. Tailored diagnosis and treatment improve outcomes. AI helps identify sex-specific risk profiles and improve diagnostic accuracy.

Key Points:

• Women show different heart disease symptoms.

• Unique risks: microvascular disease, pregnancy complications.

• Underdiagnosis is common.

• Personalized care improves outcomes.

• AI identifies sex-specific risk factors.

Track 17. Pediatric Cardiology

Pediatric cardiology deals with congenital and acquired heart diseases in children. Early diagnosis and intervention are critical to prevent complications such as heart failure and arrhythmias. Treatments include medical management and surgery. Long-term follow-up is essential. AI advances aid fetal diagnosis and treatment planning.

Key Points:

• Congenital/acquired heart diseases in children.

• Early intervention vital.

• Treatment: medical and surgical.

• Lifelong monitoring required.

• AI enhances diagnosis and care planning.

Track 18. Electrophysiology and Device Therapy

Electrophysiology studies heart electrical activity to diagnose arrhythmias. Devices like pacemakers and implantable cardioverter defibrillators treat rhythm disorders and heart failure. Side effects include infection and device malfunction. AI enhances arrhythmia detection through wearables and optimizes device settings, improving patient outcomes.

Key Points:

• Studies heart's electrical system.

• Devices: pacemakers, implantable cardioverter defibrillators.

• Risks: infection, lead issues.

• AI improves monitoring and programming.

• Better arrhythmia management.

Track 19. Heart Transplantation

Heart transplantation treats end-stage heart failure. It requires lifelong immunosuppression to prevent rejection, which increases infection and cancer risks. Complications include graft vasculopathy. AI assists in donor-recipient matching and early rejection detection using biomarker analysis, improving survival rates.

Key Points:

• Definitive treatment for end-stage heart failure.

• Lifelong immunosuppression required.

• Risks: rejection, infection, malignancy.

• AI improves matching and monitoring.

• Enhances transplant success.

Track 20. Artificial Hearts and Mechanical Support

Mechanical circulatory support devices like left ventricular assist devices help patients with severe heart failure either as bridge to transplant or destination therapy. Complications include thrombosis, bleeding, and infection. Managing these devices is complex and requires close monitoring. AI applications monitor device function and predict complications to improve patient safety and outcomes.

Key Points:

• Left Ventricular Assist Devices support failing hearts.

• Used as bridge or permanent therapy.

• Complications: thrombosis, bleeding, infection.

• Requires expert management.

• AI aids device monitoring and complication prediction.

Market Analysis Report

The global cardiovascular disease (CVD) treatment and diagnostics market is projected to grow substantially over the next 5 to 8 years, driven by a rising prevalence of heart conditions and expanding healthcare access worldwide. Valued at approximately USD 150 billion in 2025, the market is expected to reach USD 245 billion by 2032, growing at a compound annual growth rate (CAGR) of around 6.5%. Key drivers include an aging global population, which is projected to increase by over 1.5 billion people aged 60 and above by 2030, increasing the demand for cardiac care. Technological advancements such as minimally invasive surgeries, AI-enhanced imaging, wearable cardiac monitors, and telemedicine are also accelerating market growth. Additionally, growing awareness of cardiovascular health and preventive care, especially among women and high-risk groups, is creating new opportunities for early diagnosis and intervention.

Future growth opportunities lie significantly in emerging markets like Asia-Pacific, which is expected to witness a CAGR of nearly 8%, fueled by rising urbanization, expanding healthcare infrastructure, and government initiatives targeting non-communicable diseases. The integration of digital health solutions and AI-based diagnostics offers vast potential to improve patient outcomes through personalized treatment plans and remote monitoring. Moreover, innovation in regenerative medicine and targeted pharmaceuticals is set to revolutionize treatment protocols. However, challenges such as high treatment costs, regulatory complexities, and disparities in healthcare access must be addressed. Market players focusing on affordable, scalable solutions and collaborations with healthcare providers and governments are best positioned to lead this expanding sector.

Societies and Associations For heart diseases:

• American Heart Association
• European Society of Cardiology
• World Heart Federation
• American College of Cardiology
• Asian Pacific Society of Cardiology
• Canadian Cardiovascular Society
• British Cardiovascular Society
• International Society for Heart and Lung Transplantation
• Heart Failure Society of America
• Pan-African Society of Cardiology
• Japanese Circulation Society
• Brazilian Society of Cardiology
• Indian Heart Association
• Society for Cardiovascular Angiography and Interventions
• European Atherosclerosis Society
• European Heart Rhythm Association
• American Society of Echocardiography
• Heart Rhythm Society
• International Society of Hypertension
• South Asian Society on Atherosclerosis and Thrombosis

Participant benefits:

Participants will be honored with participation certificate

Specific speaker pages will be created in the website

Networking opportunities with global leaders

2 days complimentary breakfast, lunch and refreshments

Young researcher award and best poster award will be given to encourage young researchers

Submitted Abstracts will be published with High Impact Factor supporting journal with unique DOI number

Your clinic/organization name/logo will be published in our conference proceedings book and on our conference website

Past Conference Report

HEART CONGRESS 2024

The theme of Heart Disease 2024 is "Promising Growth towards Cardiac Research," with the goal of expediting scientific breakthroughs and significant achievements in the contemporary context, as well as trials and advancements in cardiology research and associated sectors. The two-day event, which will have 1000+ global events, including 300+ conferences, 500+ past and upcoming symposiums, and technical workshops, will draw cardiology practitioners from all over the world.

The goal of this Heart Diseases Conference is to provide a forum for the exchange of ideas and knowledge among cardiology professionals at all levels, including department heads, deans, directors, professors, eminent scientists, researchers, students, and medical and pharmaceutical companies, in order to improve research and development in cardiology and related fields.

Engaging, empowering, evolving, and exploring knowledge among participants from all stages of cardiology scientific research is our goal. It will draw famous scholars, specialists, and professionals from around the world and concentrate on the fundamental information and significant advancements in the quickly developing sectors.